Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
International Clinical Psychopharmacology
|
January 17, 2026
Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD)
Stefania Chaikali, Clotilde Guidetti, Madhukar H Trivedi, et al.
Molecular Psychiatry
|
March 7, 2024
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial
George I Papakostas, Madhukar H Trivedi, Richard C Shelton, et al.
International Clinical Psychopharmacology
|
May 13, 2026
Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)
Stefania Chaikali, Clotilde Guidetti, Silvia Ioannou, et al.
Journal of Affective Disorders
|
July 9, 2025
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)
Clotilde Guidetti, Stefania Chaikali, Madhukar H Trivedi, et al.
The Journal of Clinical Psychiatry
|
August 13, 2025
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD): Effect of Aripiprazole or Repetitive Transcranial Magnetic Stimulation Augmentation Versus Switching to the Antidepressant Venlafaxine on Quality of Life
Clotilde Guidetti, Stefania Chaikali, Madhukar H Trivedi, et al.
Brain Stimulation
|
December 20, 2024
Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial
Charles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
May 20, 2026
The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>
David W Goodman, Rajnish Mago, Leslie Citrome, et al.
The International Journal of Neuropsychopharmacology
|
January 13, 2026
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
Charles R Conway, Augustus John Rush, Scott T Aaronson, et al.
JAMA Network Open
|
February 25, 2026
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force
Joseph F Goldberg, Roger S McIntyre, Holly A Swartz, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
International Clinical Psychopharmacology
|
January 17, 2026
Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD)
Stefania Chaikali, Clotilde Guidetti, Madhukar H Trivedi, et al.
Molecular Psychiatry
|
March 7, 2024
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial
George I Papakostas, Madhukar H Trivedi, Richard C Shelton, et al.
International Clinical Psychopharmacology
|
May 13, 2026
Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)
Stefania Chaikali, Clotilde Guidetti, Silvia Ioannou, et al.
Journal of Affective Disorders
|
July 9, 2025
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)
Clotilde Guidetti, Stefania Chaikali, Madhukar H Trivedi, et al.
The Journal of Clinical Psychiatry
|
August 13, 2025
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD): Effect of Aripiprazole or Repetitive Transcranial Magnetic Stimulation Augmentation Versus Switching to the Antidepressant Venlafaxine on Quality of Life
Clotilde Guidetti, Stefania Chaikali, Madhukar H Trivedi, et al.
Brain Stimulation
|
December 20, 2024
Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial
Charles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
May 20, 2026
The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>
David W Goodman, Rajnish Mago, Leslie Citrome, et al.
The International Journal of Neuropsychopharmacology
|
January 13, 2026
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
Charles R Conway, Augustus John Rush, Scott T Aaronson, et al.
JAMA Network Open
|
February 25, 2026
Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force
Joseph F Goldberg, Roger S McIntyre, Holly A Swartz, et al.
Page
of 7